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Abstract 
 
Aim: Additional treatments for sepsis to be administered alongside the standard therapy 
recommended by the Surviving Sepsis Campaign have recently undergone evaluation. Due 
to its anti-bacterial, anti-inflammatory and immunomodulatory properties, intravenous 
polyvalent immunoglobulin M (IgM)–enriched immunoglobulins (IgM preparation) has been 
investigated as one of these potentially valid adjunctive therapies. The aim of this trial was to 
assess the efficacy of an IgM preparation as adjuvant therapy in the treatment of pediatric 
patients with sepsis. 
Methods: In our study, 78 septic patients admitted to a pediatric intensive care unit (PICU) at 
the University Hospital Center “Mother Teresa” in Tirana, Albania, were randomized into 
two groups (intervention and control). All patients were treated according to standard PICU 
sepsis guidelines. Additionally, patients in the intervention group received the IgM 
preparation Pentaglobin® while patients in the control group received standard sepsis therapy, 
but no immunoglobulin administration. 
Results: The survival rate was higher in the intervention group (87%, N=34) than in the 
control group (64%, N=25), and this difference was statistically significant (P=0.03). Length 
of stay (LOS) was also significantly shorter in the intervention group. 
Conclusion: In this study conducted in Albania, use of an IgM preparation, in addition to 
standard sepsis therapy, led to a significant increase in the survival rate as well as a significant 
reduction in LOS compared with placebo, when administered in PICU patients with sepsis. 
 
Keywords: bacterial infections, IgM preparation, immunoglobulin, immunotherapy, 
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Introduction 
Sepsis is a major cause of morbidity and mortality in critically ill pediatric patients (1,2). 
About 25% of all PICU admissions are due to life–threatening infections in pediatric patients 
(2). Although numerous advances in the management of critically ill children with severe 
infections have occurred in recent years, the mortality associated with severe sepsis and 
septic shock remains unacceptably high, with a rate between 20% to 56% (1,3-10). Because 
of its broad and potent activity against bacteria and their exotoxins as well as against the 
excessively activated pro-inflammatory host response, an IgM preparation was investigated as 
an adjunctive treatment for patients with severe bacterial infections (11-13). This IgM 
preparation is the only approved intravenous immunoglobulin for treating severe bacterial 
infections and contains anti- bacterial, anti-inflammatory and immunomodulatory antibodies 
from the immunoglobulin classes IgM, IgG, and IgA. In this respect, the preparation differs 
from all other standard intravenous immunoglobulin preparations, which contain almost only 
IgG (3,14,15). 
To date, there are no studies conducted in Albania assessing the efficacy of IgM preparations in 
pediatric wards. In this framework, the objective of this trial was to assess the efficacy of an 
IgM preparation as adjuvant therapy in the treatment of pediatric patients with sepsis in 
Albania. We hypothesized that administration of the IgM preparation in combination with 
standard-of-care antibiotics would increase the overall survival rate in septic patients admitted 
to PICU.  
 
Methods 
This was a prospective, double-blinded, randomized, placebo-controlled trial conducted in 
the PICU of the University Hospital Center “Mother Teresa” in Tirana, Albania, between 
January 2009 and December 2010. 
The Ethics Committee of the University of Tirana approved the study protocol and a written 
informed consent was obtained from the parents or guardians of all of the patients. The 
study was conducted in accordance with the Declaration of Helsinki and followed Good 
Clinical Practice guidelines and national regulations. The study was registered in a clinical 
trial registry. To increase patient homogeneity and to strengthen internal validity, strict 
diagnostic criteria were applied. Proven sepsis was defined according to 2001 ACCP/SCCM 
sepsis criteria (16). Patients with sepsis (SIRS, sepsis, severe sepsis, septic shock) 
documented infection and dysfunction of an organ or hypotension were enrolled in the study. 
Patients fulfilling one or more of the following criteria were not included in the study: severe 
immunosuppression, irreversible end- stage damage of vital organs, a Glasgow coma score of 
3/15, comorbidities and/or contraindications to any of the study treatments. 
One hundred and three patients were assessed for eligibility in the study. Eighteen children did 
not meet the inclusion criteria, whereas seven parents declined study participation of their 
children. 
 
Intervention 
The study utilized a parallel-group design whereby patients were stratified by baseline 
characteristics such as age and gender and also according to diagnosis and severity of disease. 
Patients were randomly assigned in a 1:1 ratio to the intervention or control group. Treatment 
assignment was randomly generated by computer in stratified permuted blocks of two. The 
intervention group received the IgM preparation while the control group did not receive any 
immunoglobulin administration (Figure 1). 
Fluid administration was protocolized. All patients received isotonic intravenous fluid bolus 
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20-40ml/kg in 1 hr. Repeated boluses were administered depending on clinical parameters, 
including heart rate, capillary refill, blood pressure, urine output and level of consciousness. 
A researcher sealed envelopes labeled only with the patient number and containing the 
respective study medication. Corresponding envelopes were opened by the researcher only 
after the enrolled participants had completed baseline assessments and were about to be 
allocated to a treatment group. Other investigators, staff, parents of the children, the nurse who 
administered the treatment and endpoint assessors were all blinded to treatment assignment. 
 
Study protocol 
All patients received standard sepsis therapy which comprised intravenous antibiotics. Patients 
in the intervention group received the IgM preparation Pentaglobin® intravenously. 
Administration of the IgM preparation was started on the day of sepsis diagnosis at a volume 
of 5 ml/kg body weight per day and was infused over six hours for three consecutive days. 
Patients in the control group received standard sepsis therapy, but no immunoglobulin 
administration. 
A detailed clinical history was taken from all cases who were also subjected to physical 
examination. Demographic data (age and gender), body weight, height, [based on which the 
body mass index (BMI) was calculated] diagnosis at PICU admission, duration of stay in the 
PICU and outcome at discharge were recorded for each patient (Table 1). Study treatment was 
administered within eight hours after randomization. Patients were observed throughout their 
stay in PICU. Compliance, laboratory parameters, vital signs, hemodynamic data laboratory 
parameters and organ dysfunction were monitored on a  daily basis. Protocol violations were 
defined before the start of the study. The study endpoint was death in PCIU. 
 
Statistical analysis 
Based on literature review and in our previous experience, the expected mortality rate in the 
control group was anticipated as 60%, whereas the magnitude of the expected treatment effect 
was set at 40%. Type I error was set as α=0.05 in a two-tailed test and type II error as β=0.05. 
The 95% confidence interval (CI) for the difference between proportions was calculated as 
follows: (D) = D - 0.236 to D + 0.236. 
After adjusting for a 5% drop-out rate, the sample size was estimated at 39 individuals in each 
group. The primary efficacy analysis was performed according to intention-to treat (ITT) 
principles, rather than as an explanatory analysis. All randomized patients were included in the 
ITT population and the per-protocol population included only patients who completed the 
treatment originally allocated in both groups.  
Normal distribution of continuous variables was tested with the Kolmogorov-Smirnov test.  
Mann-Whitney test was used to compare age, height and body weight of patients 
between the two groups.  
Chi-square test was used to compare gender differences and laboratory values in each 
treatment group and the independent sample t-test was used to compare the length of stay 
(LOS) in the PICU as well as the BMI.  
Mortality rates in the intervention and control group were compared with the chi-square test.  
The difference in survival rates between groups was assessed using the Kaplan-Meier 
method and the log-rank test. The censoring time for the survival analysis was the PICU stay 
duration.   
All statistical analyses were performed with SPSS, version 16.0. 
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Assessed for eligibility (n=103) 
 
 
 
 
Excluded (n= 25) 
 
-  Did not meet inclusion criteria (n=18) 
 
-  Declined to participate (n=7) 
 
 
 
 
Randomized (n=78) 
 
 
 
 
 
 
 
 
 
Allocated to intervention (n= 39) 
 
- Received IgM preparation (n= 38) 
 
- Did not receive IgM preparation (died) (n= 1) 
Allocation   
Allocated to control (n=39) 
 
- Received placebo (n=38) 
 
- Did not receive placebo (died) (n=1) 
 
 
 
 
 
 
           Follow-up 
 
Lost to follow-up (n= 0) 
 
Discontinued treatment (n=0) 
Lost to follow-up (n= 0) 
 
Discontinued treatment (n=0) 
 
 
 
 
 
             Analysis 
 
Included in ITT analysis (n=39) 
- Excluded from analysis (n=0) 
Included in ITT analysis (n=39) 
- Excluded from analysis (n=0) 
 
 
Figure 1. Patients included in the study  
 
 
Kola E, Çelaj E, Bakalli I, Lluka R, Kuli-Lito G, Sallabanda S. Efficacy of an IgM preparation in the treatment of 
patients with sepsis: a double-blind randomized clinical trial in a pediatric intensive care unit (Original research). 
SEEJPH 2014, posted: 09 February 2014. DOI 10.12908/SEEJPH-2014-04. 
 
6 
 
Results 
A total of 78 consecutive patients (aged from one month to thirteen years) with proven sepsis 
were included in the study after adjusting for drop-outs and non-evaluable patients. There 
were no statistical differences between treatment groups in baseline characteristics at PICU 
admission (Table 1). One patient in each group died before receiving the full course of therapy. 
A four-month old patient died on the first day of treatment in the intervention group and a six-
month old patient died on the second day of treatment in the control group. There were no 
major or minor violations of the protocol. No withdrawals, patient exclusions and or losses to 
follow-up occurred in either treatment group. Mean treatment duration in both groups was three 
days. No other concomitant treatments were given in addition to the study treatment in both 
groups. 
 
Table 1. Baseline characteristics in the ITT population 
 
Variable  Intervention group (N=39) Control group (N=39) P  
Age (years) 2.1 (3.1) (1.07 – 3.08)* 1.8 (2.7) (0.87 – 2.66) 0.6 
PICU stay (days) 5.1 (3.1) (4.08 – 6.06)* 7.1 (2.4) (6.35-7.90) <0.01 
Males (N, %) 25 (64.1) (48.4 – 77.2)† 29 (74.4) (58.9 – 85.4) 0.4 
Body weight (kg) 12.9 (8.1) (10.4 – 15.6)* 12.3 (6.9) (10.0 – 14.5) 0.7 
Height (cm) 84.7 (24.8) (76.7 – 92.8)* 83.0 (22.6) (69.9 – 87.8) 0.8 
BMI 16.7 (0.92) (16.4 – 17.0)* 16.8 (24.8) (16.5 – 17.1) 0.8 
     
* Data reported as mean (SD) (95%CI).  
† Number (%) (95%CI). 
------------------------------------------ 
 
Intention to treat analysis (ITT)  
Overall, of the 78 patients included in this study, 59 (75.6%) individuals survived. However, the 
survival rate was higher in the intervention group (87.2%, N=34) than in the control group 
(64.1%, N=25), with the difference of 23.1% being statistically significant (P=0.03). 
The odds ratio (OR) for survival was 3.8 (95%CI=1.2-11.9). A Kaplan-Meier survival analysis 
also showed a statistically significant difference in the survival rate in the intervention group 
(log-rank=4.0, P=0.04) [Figure 2]. 
Furthermore, LOS in the PICU was significantly shorter for patients in the intervention group, 
compared to the control group (5.1±3.1 days vs 7.1±2.4 days; P<0.01). 
Twelve (30.8%) children in the intervention group and nine (23.1%) in the control group were 
mechanically ventilated without a significant difference between them (P=0.6). 
Cardiac, pulmonary, renal, CNS (central nervous system) and adrenal dysfunctions were 
involved, as well as glycemic control disturbances. MODS (multiple organ dysfunction) in 
our study occurred in 8 (10.3 %) patients. 
We used hydrocortisone in 18 (23.1%) cases with catecholamine resistance and suspected or 
proven adrenal insufficiency (total cortisol concentration <18mg/dL). 
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      Figure 2. Kaplan-Meier survival analysis 
  
 
Inotropes and vasopressors were administered in 26 (33.3%) patients. There was no surgical 
procedure involved during the study period. 
The causes of death were renal failure, brain damage, hepatic failure, metabolic derangements, 
diffuse intravascular coagulation (DIC), ventilator-associated pneumonia (VAP).  
No adverse events occurred during the study period. Additionally, no fatalities occurred after 
discharge from the hospital. 
In our study we focused on anaphylactic reaction or anaphylactic shock to define an adverse 
event. Adverse reactions described in the enclosed leaflet of pentaglobine did not occur. 
Blood samples were collected daily from each treatment group for the evaluation of 
hematological and laboratory parameters (Table 2). There were no statistically significant 
differences in the total WBC count, platelets, base excess in blood, and C-reactive protein 
levels between the two groups at baseline. 
After treatment, the intervention group had statistically significant improvements in two 
inflammatory markers. Proportions of patients with C-reactive protein levels and total 
leucocyte and neutrophil counts <10000 were significantly higher in the intervention group, 
compared with controls (P=0.04 and P<0.01, respectively). 
There were no significant differences in changes in platelet counts and base excess in blood 
between treatment groups. 
 
Per-protocol analysis 
In total, 59 (77.6%) of the 76 patients who completed treatment survived. The survival rate was 
higher in the intervention group (89.5%) than in the control group (65.8%), with the difference 
being statistically significant (P=0.03). A Kaplan-Meier survival analysis also demonstrated a 
statistically significant difference in the survival rate for the intervention group, with a hazard 
ratio of 3.1 (95%CI=1.1-8.6). 
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Table 2. Patients with abnormal laboratory values before and after treatment 
 
Laboratory parameter Intervention group (N=39) n (%) of patients 
Control group (N=39)  
n (%) of patients     P  
Baseline 
WBC <10000 24/39 (61.5%) 25/39 (64.1%) NS* 
Platelets <40000 10/39 (25.7%) 9/39 (23.1%) NS 
Base excess>8 19/39 (48.7%) 20/39 (51.2%) NS 
C-reactive protein >N 29/39 (74.3%) 29/39 (74.3%) NS 
After treatment 
WBC <10000 10/39 (25.6%) 18/39 (46.2%) <0.01 
Platelets <40000 6/39 (15.4%) 8/39 (20.5%) NS 
Base excess>8 11/39 (28.2%) 20/39 (51.2%) NS 
C-reactive protein >N 12/39 (30.8%) 22/39 (56.4%) 0.04 
 
*non-significant. 
 
--------------------------------- 
 
 
Discussion 
Treatment of sepsis is complicated and typically requires a multidisciplinary approach. In 
recent years, the immunotherapeutic approach has been extensively studied but the results 
of both experimental and clinical investigations have been puzzling. The administration of 
monoclonal antibodies directed against specific sepsis mediators has produced disappointing 
results, whereas the administration of polyvalent immunoglobulins has been associated 
with better outcomes across various subgroups of patients (1,4,13). Recently, a number of 
studies have indicated that an IgM preparation is associated with reduced morbidity and an 
increased survival rate in patients with sepsis, severe sepsis or septic shock (2,14,17). In 
children, however, all the trials have been relatively small and the evidence is insufficient to 
support a robust conclusion of the benefit. 
In the present study, administration of an adjunctive IgM preparation in septic pediatric patients 
resulted in a statistically significant increase in survival rate of 23.1% in the intervention group, 
compared to control group. Another interesting result was the significantly shorter mean 
LOS in the PICU for patients receiving the IgM preparation, compared with controls. A similar 
outcome in LOS was shown in a study by El Nawawy et al. in which the mean LOS in the 
intervention group who received the adjuvant IgM preparation was significantly shorter than in 
the control group, with durations of six and nine days, respectively (2). Furthermore, a study 
published fairly recently showed that early administration of the IgM preparation is crucial. 
Delay in administration significantly increased the absolute risk of death by 2.8% every 24 
hours. Therefore, in this study, the IgM preparation was administered additionally to 
antibiotics on the day of sepsis diagnosis and study inclusion (18,19). 
In a meta-analysis comparing two types of polyvalent immunoglobulin preparations, an IgM 
preparation was found to be superior over a standard immunoglobulin preparation which 
contains mostly IgG (20). Statistically significant increases were shown in the survival rates of 
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adult and neonatal patients with sepsis and septic shock when treated with the IgM preparation 
in addition to standard sepsis therapy (11). The pooled results showed a relative reduction in 
mortality of 34% in adult sepsis patients who received the adjunctive IgM preparation (relative 
risk: 0.66; P=0.0009). The standard adjunctive immunoglobulin preparation showed a relative 
reduction in mortality of only 15% (relative risk: 0.85; P=0.04). In neonates with sepsis, a 
relative reduction in mortality of 50% was reported for the adjunctive IgM preparation 
(relative risk: 0.50; P=0.0003). The standard adjunctive immunoglobulin preparation resulted 
in a relative reduction in mortality of only 37% (relative risk: 0.63; P=0.03) (11,14,21,22). 
A head-to-head clinical trial in neonates with sepsis showed similar results. Haque et al. 
(20) conducted a clinical trial with these two different polyvalent immunoglobulin preparations 
(IgM or standard immunoglobulin preparations). A statistically significant increase in the 
survival rate in the group treated with the IgM preparation was shown when compared with the 
control group treated with the standard immunoglobulin preparation where no increase in 
survival rate was observed (8,9). Moreover, other clinical studies in neonates and children have 
shown increases in survival rates due to administration of an adjunctive IgM preparation of 
between 28%-56% (11,17,22,23) – further demonstrating a survival benefit from this 
treatment. 
Efficacy of the IgM preparation in patients of all ages is thought to be due to higher antibody 
titers against a broader variety of bacterial pathogens and their toxic products compared with 
standard immunoglobulin preparations (7,10,24). Additionally, the immune system initially 
responds with the production of IgM as the first line of defense against bacterial pathogens 
and hence IgM antibody titers increase before IgG antibody production starts (23,25). 
Moreover, IgM is more efficient in activating the complement cascade and leads to a more 
rapid and specific antibody response, compared with IgG (15,25). 
With respect to neonatal sepsis, the efficacy of an IgM preparation is possibly due to the 
relatively low IgM levels in neonates after birth. During pregnancy, only a low level of IgM is 
transferred via the placenta to the fetus and endogenous IgM production in neonates starts only 
gradually. 
 
 
Conclusion 
The use of an adjuvant IgM preparation Pentaglobin® in the treatment of pediatric sepsis 
patients resulted in an increase in the survival rate, a reduction in the LOS and an 
improvement in infection severity, all of which were found to be statistically significant in this 
study conducted in Albania. 
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